Within the last few years, several psychopharmaca, formerly used off-label, received an on-label status for drug treatment in Child and Adolescent Psychiatry (CAP) (e.g., fluoxetine, fluvoxamine, risperidone), but beyond that new options were quite rare (e.g., aripiprazole and melatonin; [1] [2] [3] ).
Also, publications on child and adolescent psychopharmacology in ECAP usually included information on single studies and reviews concerning well-known substances such as haloperidol and other neuroleptics, stimulants, atomoxetine, fluoxetine, and other SSRIs [4] . In 2011, such kind of articles presented 8.5 % (excluding a supplement on an observational trial on a methylphenidate-ER preparation [5] ) and in 2012, there appeared 7 % of the ECAP papers on that topic.
The content of most of these 2011/2012 publications reflects special aspects of psychopharmacological treatment, where management of adverse effects plays the major role (e.g., [6, 7] ) besides quality of life, satisfaction with treatment, and adherence (e.g., [8] ). The off-label use of psychopharmaca in children and adolescents is still a matter of debate either with the focus on indication or age or both. Therefore, it is welcome that Dörks et al. [9] inform us about the antidepressant drug use and off-label prescribing in children and adolescents in Germany. They report retrospectively from a large-scale population based cohort study and analyzed cross-sectional data from four German statutory health insurances (comprising about 17 % of the population from all regions in Germany; making up 2,599,685 patients up to 17 years of age). Although the prescription of SSRIs increased slowly from the 2004 to the 2006 cohort, the prescription behavior of physicians seems to reflect good clinical practice, since the use of St. Johns Wort and tricyclic antidepressants decreased. Also, prescribing antidepressants seems to be similar all over Europe, which underlines the process of harmonization in European CAP. However, the authors stated, ''that more than 50 % of children and adolescents received only a single prescription of antidepressants''. Also, a British Study [10] reported ''more than 50 % discontinued treatment after two months''. Further, ''around half of all antidepressant prescriptions were off-label with respect to age or indication'' in the Dörks et al. [9] study, but the off-label use was mostly guided by a specialist and those SSRIs were used which were recommended by clinical guidelines and/or received official on-label qualification later on.
The report of Dörks et al. [9] touches another highly important problem in childhood psychopharmacotherapy, namely, how can we improve adherence to guarantee adequate drug treatment? This topic was already reviewed and discussed in ECAP earlier [11] . The author states that ''adherence is the single most modifiable factor associated with treatment outcome … the best treatment is rendered useless if not adhered to''. In order to explore this field further, Roedelof et al. [12] investigated the treatment engagement in adolescents with severe psychiatric problems. The authors tried to answer the question how to get the highest profit possible from an evidence-based treatment applied in clinical practice. Using the Treatment Engagement Rating Scale and longitudinal latent class analysis, they identified three engagement profiles over the first year of treatment (i.e., high 39 %, medium 41 %, low 20 %). ''Only adolescents with a high engagement profile improved on global functioning''. It is recommended to measure and evaluate treatment engagement frequently and regularly to optimize treatment outcome. Similarly, the positive effect on adherence, while switching to a MPH-ER preparation, might be part of the general clinical improvement [5, 8] . The story of adherence clearly reflects that for a successful treatment, we need three things, namely an effective method, a competent specialist, and the patient who cooperates fully.
Whenever psychopharmacological aspects come into play in CAP, ethical debates are generated. Psychopharmacotherapy in children changes neuronal preconditions for cognition, emotion, and movement and thus influences brain development and related behavior. It is debated whether the latter is for the good or the worse, i.e., the riskbenefit-ratio of such medications needs to be favorable. Therefore, the ethical debate could be enriched if each article dealing with psychopharmacotherapy in minors would include an ethical consideration of the data presented. Both articles on psychopharmacotherapy in this issue of ECAP deal with important aspects having an ethical implication. Dörks et al. [9] report on off-label use and antidepressants, and Martinez-Ortega et al. [7] on weight gain while being treated with antipsychotics.
Hence, the risk of long-term effects (neuronal/metabolic) and the burden of stigma (e.g., obesity) should be discussed in relation to the evidence-based benefit of drug treatment. Both aspects should be seen not only from the patient's perspective, but-while including adherencealso from the doctor's view.
It is widely accepted that we must safeguard children's rights [13] with ''five ethical dimensions: human rights, validity, distributive justice, beneficence/nonmaleficence, and respect for autonomy/justice'' [14] . In case of the topics ''off-label'' and ''weight gain'', the treatment approach should be clearly and fully explained and ''a joint decision-making model that involves children, caregivers and the treating physician will best meet the needs of mentally ill children and adolescents'' [13] . Minimal burden and risk for the patient should be the guideline weighted against therapeutic efficiency to optimize the risk-benefit-ratio. What quite often is neglected during such a ''joint decision process'' is the long-term cooperation needed from the patient's side and how this cooperation should take place with mutual daily clinical duties and responsibilities. In other words, ethical responsibility of the professional is one part (and already heavily discussed), but ethical responsibility of the patient/client is also needed for a therapeutic outcome and prognosis-and should therefore also be demanded during professional and trialogue debates. Otherwise, we will have an ethically unbalanced treatment situation, e.g., leading to problems with adherence, followed by non-successful treatments with unnecessary costs for the society. Haynes [15] even argues that ''Increasing the effectiveness of adherence interventions may have a far greater impact on the health of the population than any improvement in specific medical treatments''.
If this holds true, adherence cannot be reduced to a private duty as the question of resource allocation comes into play on a societal level: Is it ethical to invest lots of time and may be expensive medication in a therapy of a single person if this very person or its legal guardian does not appreciate this, stops medication (already after a single prescription-see above), or does not adhere to the therapy plan although it was discussed and agreed at first? Is this an ethically unsolvable dilemma between autonomy of the client/patient and his/her socio-ethical responsibility?
Of course, in general ''Patients need to be supported, not blamed'' (WHO 2003: Adherence to Long-Term Therapies-Evidence for Action; Take home messages. http:// apps.who.int/medicinedocs/en/d/Js4883e/5.html, download: 10th June 2013). But this should not lead to a kind of ''patient pampering'' on the costs of others in the very sense of the word. To avoid blaming, it seems helpful to ask the following questions beforehand and while monitoring the treatment process:
1. Are there any reasons for the non-adherence the therapy team is not aware of like being afraid of negative side effects or any misunderstanding, any barriers in daily life to organize regular medication intake, etc.? 2. Which role plays the diagnosis/disease itself concerning low adherence? E.g., many psychiatric illnesses lower self-reflection and concentration/memory. And if so, how can adherence be supported in these cases? 3. If adherence would be objectively possible but is not given, how long/often should the physician try to motivate the caregiver/patient to adhere? Or the other way around: can we think of concrete situations where it may be justified to deny further treatment?
These and further ethical questions concerning treatment adherence cannot be discussed in detail here. But we would like to encourage a debate reflecting these issues as they seem to be of particular urgency when parents or other legal guardians deny treatment adherence concerning children, which may have negative consequences for the child's life that may not be reversible later on.
Because of its immense importance, it would be favorable to measure or even predict adherence.
So, separately from the recent ECAP issue, the topic of adherence and its operationality came to our attention when the Jury for the ''ECAP ADHD Paper of the Year 2012'' 1 made its decision. One of the two winners is Maite Ferrin from London (Ferrin et al. [16] ''Evaluation of attitudes towards treatment in adolescents with attention deficit hyperactivity disorder (ADHD)''). She found it ''important to disentangle the specific attitudes that contribute to treatment adherence''. She developed and practically tested a Questionnaire on Attitudes Towards Treatment (QATT) which may help clinicians to predict treatment adherence, and thus helping to fit together the best treatment option and the best cooperation between parties.
Together with this clinical paper also a basic research paper, lead by Monique Bloemsma from Ghent, was awarded (Bloemsma et al. [17] ''Comorbid anxiety and neurocognitive dysfunctions in children with ADHD''). The main message of this study (with improved neuropsychological methodology and a careful analysis) is that the child's perspective on comorbid anxiety in ADHD ''shows foremost the largest associations with the neurocognitive dysfunctions'' compared with the reports of anxiety rated by parents and teachers. ''This stresses the importance of including child self-reported anxiety assessments in clinical and research practice'', especially if cognitive problems are reported.
Altogether, these examples show that ECAP has to offer good research which may be valued and practically implemented by many readers.
